CONRAY 43 Rx
Generic Name and Formulations:
Iothalamate meglumine 430mg/mL; soln for IV infusion; organically bound iodine 202mg/mL.
Indications for CONRAY 43:
For use in lower extremity venography, IV infusion urography, contrast enhancement of computed tomographic brain images and arterial digital subtraction angiography. For enhancement of computed tomographic scans performed for detection and evaluation of lesions in the liver, pancreas, kidneys, abdominal aorta, mediastinum, abdominal cavity and retroperitoneal space. For use in retrograde cystography, cystourethrography and retrograde pyelography.
Adults and Children:
Lower extremity venography: 30–125mL per lower extremity; reduce dose in children based on body weight. IV infusion urography: infuse at a rate of 40–50mL/min. 3mL/kg; max 200mL. Non-neoplastic conditions: 3mL/kg IV; max 200mL. Contrast enhanced in body computed tomography: 200–250mL by bolus inj, rapid infusion or combination of both; children: reduce dose based on body weight. Arterial digital subtraction aniography: Carotid or vertebral arteries: 3–10mL; Aortic arch: 15–30mL; Subclavian and brachial arteries: 5–15mL; Major branches of the aorta: 5–30mL; Abdominal aorta: 10–30mL; max 200mL. Retrograde pyelography: 25mL for bilateral and 15mL for unilateral pyelograms; about 5–6mL are usually administered for each exposure; children: usually require a volume reduced in proportion to body size. Cystography and cystourethrography: adults: 200–400mL; children: 30–300mL.
Myelography. Others: see full labeling.
Not for intrathecal use. Should be administered by professional trained in use of radiopaque agents in appropriate facilities with emergency treatment readily available. Avoid in homocystinuria. Subarachnoid hemorrhage. Multiple myeloma. Pheochromocytoma. Homozygous sickle cell disease. Primary or metastatic cerebral lesions; risk of convulsions. Advanced renal disease. Combined renal and hepatic disease. Severe hypertension. CHF. Recent renal transplant. Diabetes. Diabetic nephropathy. Hyperthyroidism. Endotoxemia. Elevated body temperatures. History of asthma/allergy. Elderly. Maintain adequate hydration. Pregnancy (Cat.B - Conray 30, 60; Cat.C - Conray 43). Nursing mothers: not recommended; avoid breastfeeding for 24hrs post-procedure.
Radiopaque contrast medium.
GI upset, facial flushing, body warmth; hypersensitivity reactions, cardiovascular reactions (eg, vasodilation, flushing, venospasm), inj site reactions, neurological reactions (eg, spasm, convulsions, aphasia, syncope, coma, death), endocrine reactions (eg, hypothyroidism), headache, shaking, chills, nephropathy.
Conray 30: Bottles (150mL)—12; Conray 43: Vials (50mL)—50; Bottles (250mL)—12; Conray 60: Vials (30mL, 50mL)—50; Bottles (100mL, 150mL)—12
Endocrinology Advisor Articles
- Effect of HbA1c and Perioperative Glucose on Postoperative Mortality
- GLP-1 Agonists Superior to DPP-4 Inhibitors for Reducing HbA1c, Weight in T2D
- Semaglutide May Be Useful for Treating Obesity in People Without Diabetes
- Effect of Growth Hormone Treatment on BMD in Adults With Prader-Willi Syndrome
- Once-Daily Oral Contraceptive for Men Shows Promise
- American College of Physicians Releases 4 Guidelines for HbA1c Targets in T2D
- Dyslipidemia Drug Indications
- No Difference in Weight Loss Outcomes With Low-Fat vs Low-Carbohydrate Diet
- Damaging Effects of Gastric Bypass Surgery on Bone Mass and Microarchitecture
- Gastric Bypass Surgery Linked to Increased Risk for Nonvertebral Fractures
- Metformin May Improve Pregnancy Outcomes in Polycystic Ovary Syndrome
- HbA1c Levels Affect Serum Phospholipids, Inflammation inT2D, CVD
- No Cardiovascular Benefit With Fenofibrate in T2D and Hypertriglyceridemia
- Cardiovascular Function May Improve After Cure of Cushing Syndrome
- Primary Prevention Outcomes With Aspirin in T2D and Heart Failure